文档介绍：Audit in VTE prevention
Peter Davies
Senior Pharmacist
Drivers for audit
Venous thromboembolic prevention is a DH patient safety priority
NICE clinical guideline venous thromboembolism reducing the risk
CQUIN
The NHS standard contract for acute services and VTE prevention
Audit of VTE currently being undertaken by the Trust
VTE risk assessment audit
Clinical incident/Pharmacy intervention monitoring
Healthcare record audit
Root cause analysis of hospital
acquired thrombosis
Rivaroxaban use in elective THR and TKR
VTE risk assessment
Audit data since June 2008
Data collected from the front of the drug administration and record chart
3 monthly data until May 2010 now monthly
CQUIN requirements
VTE risk assessment audit results
Clinical incident and Pharmacy intervention reporting
Reporting forms adapted to include fields to record incidents and interventions relating to VTE prevention and prophylaxis
Report generated by clinical risk and sent monthly to the mittee
Healthcare records audit
Data provided by individual wards
Audit of 5 sets of healthcare records
Record data on whether risk assessment and thromboprophylaxis is appropriate on an electronic data collection form
Data collated by clinical audit and forwarded to the mittee
Root cause analysis of hospital acquired thrombosis
Hospital acquired thrombosis detected by
DVT/Anticoagulant clinic
Coding
Diagnostics
Autopsies
Subjected to a root cause analysis
Reviewed by the mittee
Rivaroxaban thromboprophylaxis following elective THR and TKR
For elective Primary THR or TKR
First dose 30 hours post surgery
14 days for TKR and 35 days for THR
Contra-indicated e-GFR <30ml/min
Not used if on long term anticoagulant